Default company panoramic image
Logo

Epigentix Inc

Developing drugs utilizing novel epigenetic pathways to fill unmet medical needs. First applications are the most severe forms of cancer.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Delray Beach, FL, USA
  • Currency USD
  • Founded December 2011
  • Employees 2
  • Website epigenetix.net

Company Summary

Develop drugs to address unmet medical needs using cutting edge Epigenetic mechanisms.

Team

  • Default avatar
    Claes Wahlestedt
    CSO Founder PHD MD

    Claes Wahlestedt, M.D., Ph.D., an internationally recognized researcher of novel drug therapies for neuropsychiatric disorders and epigenetics, is the director of the Center for Therapeutic Innovation and associate dean for therapeutic innovations at the John P. Hussman Institute for Human Genomics. A founding faculty member and professor of neuroscience and molecular therapeutics at the Florida campus of The Scripps Research Institute.

  • Default avatar
    Jeffrey Albert
    Director of Chemistry PHD

    14 year track record in the identification and validation of new drug targets, discovering initial chemical leads, and in advancing those leads through pre-clinical discovery. As project leader he advances multi-disciplinary project teams from concept to pre-clinical toxicology. With a background in Chemistry and Biochemistry, he also leads chemistry teams in design, chemical synthesis and optimization.
    22 scientific publications, 26 patents.

  • Default avatar
    Joseph Collard
    CEO

    Co-Founded Epigenetix Inc, Curna Inc (sold to Opko 2011) , Sumpraxis and Technisource ( took public 1987 sold 2002) . In all cases worked at CEO level and intimately involved in Technology and Strategy.
    Specialties: Strategic Investment, Biotech, Project Planning, Business Development, Scientific Software Applications.

    Working to make the world better by starting and funding companies.

  • Default avatar
    Shuan Brothers
    Advisor PHD

    Founding member of the Center for Therapeutic Innovation.

    Specialties: G protein coupled receptor signaling, epigenetics, cell biology, drug discovery, writing

  • Default avatar
    Nagi Ayad
    Advisor Cancer PHD

    Dr. Ayad is a cell biologist by training and has worked on enzymatic regulation of mitotic cell divisions in neuronal precursors. Dr. Ayad received his Ph.D. degree from Yale Medical School in 1998 and completed his postdoctoral training from Harvard Medical School in 2004. He served as an assistant professor at the Scripps Research Institute in Jupiter, Florida prior to joining UofM.

  • Default avatar
    Jan Norelid
    CFO

    CFO 11 years for NASDAQ companies, including reverse merger and secondary offering.
    CFO of public and private companies in bio-tech, medical device, consumer goods, and other industries

Advisors

  • Default avatar
    Jon Cole Edwards Wildman
    Lawyer
    Unconfirmed
    Default avatar
    Carter Strong JD CPA www.linkedin.com/pub/carter-strong/5/a95/1a0
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Joe Collard
    Unconfirmed